Aldevron

We serve the biotech industry by manufacturing high quality biologics, impacting lives worldwide.
🔸Plasmid DNA 🔸mRNA 🔸Proteins
Discovery➡Clinical➡Commercial

[Aldevron @aldevron]

#mRNA developers face challenges to meet standards for #clinical applications. In our webinar, Developing Processes for Successful Clinical-Grade mRNA Manufacturing, our experts discuss the importance of process development to meet those standards. https://t.co/0zsQhEknC5

[Aldevron @aldevron]

Non-viral modalities in dealing with #genetherapy and #celltherapy are becoming a larger consideration for #therapeutics developers, as Pat Paez discusses in a presentation from #BiotechWeekBoston https://t.co/Wlv4ovBQ2w

[Aldevron @aldevron]

ICYMI Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA https://t.co/yMqDm7YFO7

[Aldevron @aldevron]

Advancement and evolution. Alex Liu discusses how they are affecting the potential for #celltherapy and #genetherapy as he looks forward to continuing the journey of transformative therapies. https://t.co/tib63yimUp

[Aldevron @aldevron]

#bipProcessUK's annual meeting starts Tuesday in Liverpool! Take the opportunity to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs at booth 30 and see what we have to offer https://t.co/Qe5jdfUEFq

[Aldevron @aldevron]

Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA https://t.co/MODdOtjvpK

[Aldevron @aldevron]

Meet us in Liverpool for the #bipProcessUK annual meeting to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs. Visit with Stuart King and Clare Whitewoods at booth 30 and see what we have to offer https://t.co/LVg8QROF1l

[Aldevron @aldevron]

#Capping efficiency is one of the concerns as #mRNA becomes widely used, with several options now available that can improve that efficiency, with RNA #polymerase being a key factor for consideration https://t.co/uGKoMDRzJp

[Aldevron @aldevron]

An exciting agenda is coming up @mrnaconference in Boston, Nov 12-14. Meet Aldevron’s experts to discuss the latest in #mRNA and what the future holds. Don’t miss Tao Lu’s presentation on mRNA manufacturing strategies on Nov 14 #mRNA2024 https://t.co/G44xiY5skn

[Aldevron @aldevron]

ICYMI #CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms https://t.co/L71bJoQAja

[Aldevron @aldevron]

#CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms. https://t.co/OgcDYKfBcI

[Aldevron @aldevron]

ICYMI #Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. https://t.co/4rSN0dh91E

[Aldevron @aldevron]

#Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. https://t.co/bh26MWt8SY

[Aldevron @aldevron]

ICYMI #mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase https://t.co/judDIJKn95

[Aldevron @aldevron]

Early in your clinical programs? Aldevron’s new small-scale cGMP service for up to 500mg of plasmid DNA deliverables helps you advance your work. Trust your pDNA partner has been providing clients with the highest quality products and services since 1998. https://t.co/pMiqGEGP6o

[Aldevron @aldevron]

ICYMI Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase https://t.co/QkhqV0Qj3y

[Aldevron @aldevron]

#mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase https://t.co/XyJTAAZ6Pi

[Aldevron @aldevron]

Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase https://t.co/4E5XA1S5FD

[Aldevron @aldevron]

ICYMI Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics https://t.co/GXKh228LZo

[Aldevron @aldevron]

Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics https://t.co/4cO2vAy3rl